The Centers For Medicare And Medicaid Services Has Granted A Product-specific Procedure Code Icd-10-PCS For Abeona Therapeutics' Prademagene Zamikeracel (Pz-cel), Investigational Autologous Cell-based Gene Therapy Currently In Development For Recessive Dystrophic Epidermolysis Bullosa
Portfolio Pulse from Benzinga Newsdesk
The Centers for Medicare and Medicaid Services (CMS) has granted a product-specific procedure code ICD-10-PCS for Abeona Therapeutics' investigational gene therapy, Prademagene Zamikeracel (Pz-cel). This code will facilitate efficient documentation, billing, and analysis of inpatient hospital procedures using Pz-cel if it receives U.S. marketing approval. The code will be effective from October 1, 2024.
August 13, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CMS has granted a product-specific procedure code ICD-10-PCS for Abeona Therapeutics' investigational gene therapy, Prademagene Zamikeracel (Pz-cel). This will aid in efficient documentation, billing, and analysis if Pz-cel receives U.S. marketing approval. The code will be effective from October 1, 2024.
The granting of a product-specific procedure code by CMS is a positive regulatory development for Abeona Therapeutics. It indicates progress in the regulatory pathway for Pz-cel and will facilitate future documentation and billing processes if the therapy receives marketing approval. This news is likely to have a positive short-term impact on ABEO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100